JP2000504579A5 - - Google Patents

Download PDF

Info

Publication number
JP2000504579A5
JP2000504579A5 JP1997528984A JP52898497A JP2000504579A5 JP 2000504579 A5 JP2000504579 A5 JP 2000504579A5 JP 1997528984 A JP1997528984 A JP 1997528984A JP 52898497 A JP52898497 A JP 52898497A JP 2000504579 A5 JP2000504579 A5 JP 2000504579A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1997528984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000504579A (ja
Filing date
Publication date
Priority claimed from DE19605548A external-priority patent/DE19605548A1/de
Application filed filed Critical
Publication of JP2000504579A publication Critical patent/JP2000504579A/ja
Publication of JP2000504579A5 publication Critical patent/JP2000504579A5/ja
Abandoned legal-status Critical Current

Links

JP9528984A 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物 Abandoned JP2000504579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19605548.2 1996-02-15
DE19605548A DE19605548A1 (de) 1996-02-15 1996-02-15 Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
PCT/EP1997/000649 WO1997030170A1 (de) 1996-02-15 1997-02-13 Zusammensetzung für die transfektion höherer eukaryotischer zellen

Publications (2)

Publication Number Publication Date
JP2000504579A JP2000504579A (ja) 2000-04-18
JP2000504579A5 true JP2000504579A5 (enExample) 2004-11-18

Family

ID=7785445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9528984A Abandoned JP2000504579A (ja) 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物

Country Status (6)

Country Link
EP (1) EP0900281A1 (enExample)
JP (1) JP2000504579A (enExample)
CA (1) CA2246227A1 (enExample)
DE (1) DE19605548A1 (enExample)
MX (1) MX9805507A (enExample)
WO (1) WO1997030170A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766705B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
GB0120022D0 (en) * 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN110121352B (zh) 2016-09-01 2020-12-11 嵌合体生物工程公司 Gold优化的car t-细胞
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
EP3790896A1 (en) 2018-05-07 2021-03-17 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
JPWO2020213724A1 (enExample) 2019-04-19 2020-10-22
CN113905757B (zh) 2019-06-05 2026-01-13 中外制药株式会社 抗体切割位点结合分子
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
EP4310188A1 (en) 2021-03-17 2024-01-24 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
WO2022214887A1 (en) 2021-04-08 2022-10-13 Phosphogam, Llc Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
JPWO2024150525A1 (enExample) 2023-01-12 2024-07-18

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition

Similar Documents

Publication Publication Date Title
JP2000504603A5 (enExample)
JP2000505325A5 (enExample)
JP2000506816A5 (enExample)
JP2000504753A5 (enExample)
JP2000512172A5 (enExample)
JP2000508486A5 (enExample)
JP2000508367A5 (enExample)
JP2001506266A5 (enExample)
JP2000510176A5 (enExample)
JP2000512140A5 (enExample)
JP2000509167A5 (enExample)
JP2000514722A5 (enExample)
JP2000502937A5 (enExample)
JP2000504828A5 (enExample)
JP2000510221A5 (enExample)
JP2000507739A5 (enExample)
JP2000512980A5 (enExample)
JP2000510714A5 (enExample)
JP2000513361A5 (enExample)
JP2000507557A5 (enExample)
JP2000507296A5 (enExample)
JP2000506005A5 (enExample)
JP2000504731A5 (enExample)
JP2000508049A5 (enExample)
JP2000503889A5 (enExample)